Author Archives: Ben Comer

Clayton Christensen on the Future of Pharma

By Ben Comer | Published: May 11, 2012
A keynote speaker at the 9thAnnual SaS Health Care & Life Sciences Executive Conference on May 10, ‘disruptive’ author of The Innovator’s Dilemma and Harvard business professor Clayton Christensen sat down with PharmExec to discuss the future of the pharmaceutical industry, and what Mitt Romney could bring to the White House.
Posted in Biotech, Events, FDA, IP, People, R&D, Regulatory, Safety, Technology, Uncategorized, healthcare, leadership | Tagged , , , , , , , , , , , , | Leave a comment

Using Social Networks to Increase Sales

By Ben Comer | Published: May 8, 2012
Social networks existed long before Mark Zuckerberg came along. What hasn’t existed until recently are the tools, metrics and case studies necessary to understand how physicians influence each other within professional networks, and how these relationships can be used to change prescribing behavior.
Posted in Advertising, Marketing, Sales, Strategy, Technology, leadership, social media | Tagged , , , , , , , , , , | Leave a comment

CETP Inhibitors: Blockbusters that Never Ran?

By Ben Comer | Published: May 7, 2012
The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.
Posted in Biotech, R&D, Technology, leadership | Tagged , , , , , , , | Leave a comment

Heady Ideas for Digital Health Marketing

By Ben Comer | Published: May 1, 2012
If you really want to know what’s on a patient’s mind, it’s best to skip the small talk and go straight to the brain waves, as demonstrated by Neuro Insight CEO Pranav Yadav in the lead-off presentation yesterday at Chandler Chicco’s Pioneers in Digital Health conference.
Posted in Advertising, Agency Insight, E-Media, Events, Marketing, Patient Communication, Sales, Strategy, Technology, leadership, social media | Tagged , , , , , , , | Leave a comment

Dare to Compare: Genzyme Bets on MS

By Ben Comer | Published: April 25, 2012
Riding positive data on a late-phase multiple sclerosis drug, Genzyme execs talked up the company’s willingness to go head-to-head against Rebif, EMD Serono and Pfizer’s blockbuster beta interferon. Genzyme execs didn’t go so far as to reiterate former CEO Henri Termeer’s 2010 prediction of $3 billion plus in potential sales for Lemtrada (alemtuzumab), but [...]
Posted in Biotech, Events, FDA, Global, IP, R&D, Regulatory, Safety, Sales, Strategy, Technology | Tagged , , , | Leave a comment